These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Beneficial actions of antagonism of peptide leukotrienes in hemorrhagic shock. Bitterman H, Smith BA, Lefer AM. Circ Shock; 1988 Mar; 24(3):159-68. PubMed ID: 3383353 [Abstract] [Full Text] [Related]
6. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock. Bitterman H, Smith BA, Lefer AM. Arzneimittelforschung; 1988 Oct; 38(10):1389-93. PubMed ID: 3196378 [Abstract] [Full Text] [Related]
7. Salutary consequences of blockade of platelet activating factor in hemorrhagic shock. Stahl GL, Bitterman H, Terashita Z, Lefer AM. Eur J Pharmacol; 1988 May 10; 149(3):233-40. PubMed ID: 3409951 [Abstract] [Full Text] [Related]
8. Mechanisms of action of PGE1 in hemorrhagic shock in rats. Bitterman H, Stahl GL, Terashita Z, Lefer AM. Ann Emerg Med; 1988 May 10; 17(5):457-62. PubMed ID: 3364825 [Abstract] [Full Text] [Related]
9. Beneficial effect of anisodamine in hemorrhagic shock. Su J, Hock CE, Lefer AM. Naunyn Schmiedebergs Arch Pharmacol; 1984 Apr 10; 325(4):360-5. PubMed ID: 6728045 [Abstract] [Full Text] [Related]
10. Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock. Bitterman H, Lefer DJ, Lefer AM. Methods Find Exp Clin Pharmacol; 1987 Jun 10; 9(6):341-7. PubMed ID: 3116357 [Abstract] [Full Text] [Related]